National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

The MERIT Award

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

NCI Research Coding and Reporting

NCI Training and Career Development Inventory

caBIG: Connecting the Cancer Community
MERIT Award Recipient: Robert N. Eisenman, Ph.D.

Robert N. Eisenman   Sponsoring NCI Division:  Division of Cancer Biology
Grant Number:R37CA057138
Award Approved:September 2003
Institution:Fred Hutchinson Cancer Research Center
Department:Basic Sciences
Scientific Abstract (CRISP)
Robert N. Eisenman at the Fred Hutchinson Cancer Research Center
Literature Search on PubMed

Myc Oncoprotein Function

The Eisenman laboratory is focused on understanding how cell proliferation, growth, and differentiation are regulated through the actions of specific transcription factors. Over the last decade they have focused on a network of interacting transcription factors--the Max network--whose components together comprise a transcriptional switching system that has been highly conserved throughout evolution. One of the components of the network is the Myc oncoprotein, the product of a cancer gene profoundly involved in the genesis of many different tumors, but also normally involved in cell proliferation, differentiation, and death. Myc does not function alone, but interacts in a highly specific manner with its dimerization partner, Max, permitting the Myc-Max heterodimer to bind DNA (at the E-box sequence CACGTG) and regulate gene expression.

Importantly, Max also interacts with other proteins, including a group called the Mad family. Whereas Myc-Max dimers activate transcription at E-box sites, Mad:Max heterodimers repress transcription at the same sites and thus appear to oppose the gene activation function of Myc:Max. Normally, Mad is expressed during the terminal differentiation of many cell types, at a time when Myc is usually turned off. The Eisenman laboratory has been able to demonstrate switching of Myc-Max to Mad-Max complexes during differentiation of several cell types. They have also shown that Max interacts with other interesting bHLHZ proteins including Mga and Mnt. The balance between these proteins is likely to be critical for determining the behavior of cells.

Protein interactions also govern the transcriptional activities of these proteins. They have shown that Mad represses transcription by binding to the co-repressor mSin3 which in turn interacts with Class I histone deacetylases. A major project in the lab is directed towards understanding the structural basis and specificity of the Mad-Sin3 interaction as well as elucidating the broader functions of mSin3 in development.

They have also identified conserved versions of Myc, Max and Mad proteins in the fruit fly Drosophila melanogaster and are using this powerful genetic model in order to elucidate the normal functions and global gene targets of the network proteins more fully. Information gleaned from the Drosophila system can be immediately applied to mammalian cells. Finally, the Eisenman lab is using Myc's ability to rapidly cause lymphomas in mice as a means of discovering genes that cooperate with Myc in the development of tumors.

Back to TopBack to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov